
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc is poised for growth as it raises its FY26 EPS estimates, reflecting a more favorable financial outlook due to a higher share count. The anticipated approval of the MyoVista device, alongside the rollout of the MyoVista Insights cloud platform and a likely FDA approval of its first diagnostic algorithm by the first half of 2026, underscores significant market potential. The company's strategic positioning and technological advancements paint a promising picture for its future in the medical technology sector.
Bears say
HeartSciences Inc. faces significant challenges that contribute to a negative outlook on its stock, largely stemming from substantial FDA-related delays that have resulted in a drastic reduction of its FY2026 revenue estimate from $1.2 million to only $0.1 million. Additionally, the company is confronted with various risks, including balance sheet and liquidity issues, potential failures in product safety and efficacy during clinical trials, and difficulties in achieving necessary regulatory approvals and commercial viability for its product offerings. Furthermore, external factors such as competitive pressures, evolving macroeconomic conditions, and shifting investor sentiment in the healthcare sector may exacerbate the challenges faced by HeartSciences, undermining its growth prospects.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares